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A polybasic motif in ErbB3-binding protein 1 (EBP1) has key functions
in nucleolar localization and polyphosphoinositide interaction
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*NucReg Research Program, Department of Molecular Biology, University of Bergen, 5008 Bergen, Norway
Polyphosphoinositides (PPIns) are present in the nucleus where
they participate in crucial nuclear processes, such as chromatin
remodelling, transcription and mRNA processing. In a previous
interactomics study, aimed to gain further insight into nuclear
PPIns functions, we identified ErbB3 binding protein 1 (EBP1)
as a potential nuclear PPIn-binding protein in a lipid pull-down
screen. EBP1 is a ubiquitous and conserved protein, located
in both the cytoplasm and nucleolus, and associated with cell
proliferation and survival. In the present study, we show that
EBP1 binds directly to several PPIns via two distinct PPIn-binding
sites consisting of clusters of lysine residues and positioned at
the N- and C-termini of the protein. Using interaction mutants,
we show that the C-terminal PPIn-binding motif contributes the
most to the localization of EBP1 in the nucleolus. Importantly,
a K372N point mutation, located within the C-terminal motif
and found in endometrial tumours, is sufficient to alter the
nucleolar targeting of EBP1. Our study reveals also the presence
of the class I phosphoinositide 3-kinase (PI3K) catalytic subunit
p110β and its product PtdIns(3,4,5)P3 together with EBP1 in the
nucleolus. Using NMR, we further demonstrate an association
between EBP1 and PtdIns(3,4,5)P3 via both electrostatic and
hydrophobic interactions. Taken together, these results show
that EBP1 interacts directly with PPIns and associate with
PtdIns(3,4,5)P3 in the nucleolus. The presence of p110β and
PtdIns(3,4,5)P3 in the nucleolus indicates their potential role in
regulating nucleolar processes, at least via EBP1.
Key words: EBP1, interaction, nucleolus, p110β, PI3K,
PIP3.
INTRODUCTION
Phospholipids are well known to play fundamental roles not
only as structural components of membranes but also in
signal transduction pathways initiated at the plasma membrane.
However they have also emerged as essential components
of the nucleus not only in the nuclear envelope but also
within nuclei, in the nuclear matrix and in association with
the chromatin [1,2]. This endonuclear pool of phospholipids
represents approximately 6–10% of the total cell composition
of phospholipids [3]. Polyphosphoinositides (PPIn nomenclature
from [4]), which consist of seven phosphorylated derivatives of
phosphatidylinositol (PtdIns), are also present within the nucleus
together with the enzymes that regulate their interconversion [5–
8]. With the exception of PtdIns(3,4)P2 and PtdIns(3,5)P2, the
other five PPIns have been detected within the nucleus deprived
of their nuclear envelope, by radiolabelling and mass assays
[9–14], electron microscopy or by immunofluorescence using
specific PPIn probes or antibodies [15–20]. PPIns regulate nuclear
processes, such as protein–chromatin association, transcription,
pre mRNA processing, splicing and export as well as cell cycle
progression [21–25], by interacting with proteins containing
PPIn-binding domains [26] or polybasic regions (PBR)/K/R
motifs [24,27]. Mono-phosphorylated PPIns were shown to
interact with Pf1 (plant homeodomain zinc finger 1) [28], SAP30L
(Sin3A-associated protein 30 like) [29] and ING2 (inhibitor of
growth protein 2) [30,31], proteins known to bind the co-repressor
Sin3A. PPIns-interaction was further shown to regulate SAP30L
and ING2 association to chromatin [13,29,30]. BRG1 (Brahma
related gene 1), a component of the chromatin remodelling
BAF complex, binds to PtdIns(4,5)P2 and this interaction
regulates E-actin association to the complex [32,33]. Nuclear PPIn
functions include also pre-mRNA processing such as splicing and
polyadenylation as well as mRNA export to the cytoplasm [17–
19,34,35]. A pool of PtdIns(4,5)P2 present in nuclear speckles
binds to and regulates the activity of the poly(A) polymerase
Star-PAP [nuclear speckle targeted PIPKIα regulated-poly(A)
polymerase] [36]. Furthermore, ALY (alias THO complex subunit
4) binds to both PtdIns(4,5)P2 and PtdIns(3,4,5)P3, an interaction
essential for its localization to nuclear speckles and mRNA export
[35,37]. Regarding transcriptional regulation, several studies have
correlated gene expression to the interaction of the nuclear
receptors SF-1 (steroidogenic factor-1) and LRH-1 (liver receptor
homologue-1) with PtdIns(4,5)P2 and PtdIns(3,4,5)P3 in the
ligand binding pocket [38–41] and the basal transcription factor
TAF3 (TATA box binding protein-associated factor 3) to several
PPIns via a PBR [42]. PtdIns(4,5)P2 was also shown to bind to
BASP1 (brain acid soluble protein 1) and this interaction promotes
a co-repressive function by recruiting histone deacetylases [43].
Other data correlate changes in the levels of nuclear PPIns to
cell cycle progression [12,44,45] or apoptosis via an interaction
between nucleophosmin (NPM) and PtdIns(3,4,5)P3 [46].
These studies clearly show the importance of PPIns in the
nucleus but they represent only a few examples of nuclear PPIn-
binding proteins. To further define the global significance of
nuclear PPIns, we have previously established a quantitative
proteomic method to identify nuclear PPIn-interacting proteins
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[24]. Using SILAC metabolic labelling, lipid pull-down and
MS, we identified 28 nuclear proteins as potential PtdIns(4,5)P2-
binding proteins, among which ErbB3 binding protein 1 (EBP1),
alias proliferation-associated protein 2G4 (PA2G4). EBP1 is
conserved through evolution and ubiquitously expressed [47–49].
Human EBP1 was originally identified as a binding partner of
the tyrosine kinase receptor ErbB3 [50] and as the homologue
of murine p38-2AG4 [47]. PA2G4 encodes two splice variants, a
long and predominant form p48, and a shorter and minor form p42
(homologue to p38-2G4) which differs in its N-terminus by the
lack of the first 54 amino acids [51]. The two isoforms have distinct
sub-cellular localizations, p48-EBP1 is present in the cytoplasm,
nucleus as well as the nucleolus [52,53], whereas p42-EBP1 is
restricted to the cytoplasm, where it is targeted for degradation via
its ubiquitination [51,54]. p48-EBP1 has the ability to translocate
from the cytoplasm to the nucleus upon the activation of ErbB3
[50] or upon high cell density in oral squamous carcinoma
cells [55].
In the present study, we show that EBP1 binds directly to
several PPIn species via two different PPIn interaction sites
consisting of lysine-rich PBRs located in the two termini of the
protein. The two PBRs have a different PPIn-interaction profile
and contribute to EBP1 nucleolar localization, albeit differently.
EBP1 interacts particularly with PtdIns(3,4,5)P3 via its C-terminal
PBR and this association is localized in the nucleolus. The C-
terminal PBR is mutated in endometrial cancer and we showed
that this partially prevents PtdIns(3,4,5)P3-interaction as well
as its nucleolar localization. These data demonstrate that the
EBP1 PBRs have a dual function as a PPIn interaction motif
and nucleolar localization signal, and imply that the regulation
of EBP1-mediated nucleolar processes is potentially regulated by
PtdIns(3,4,5)P3.
MATERIALS AND METHODS
Plasmids, cloning and site-directed mutagenesis
The phospholipase Cδ1 pleckstrin homology domain (PLCδ1-
PH) cloned in pGEX-4T was obtained from Dr A.Z. Gray
(University of Dundee, UK) and the general receptor for
phosphoinositides-1 PH domain (GST-GRP1-PH) cloned in
pGEX-4T3 was from Dr J. Hastie (MRC, University of Dundee,
UK). pGEX-4T2-hEBP1 and pEGFP-C2-hEBP1 were from
M. Squatrito [53]. The N- and C-terminal EBP1 fragments
were amplified by PCR from pGEX-4T2-hEBP1 using primers
flanked by EcoRI restriction sites and cloned into pGEX-
4T1. All mutants were generated by QuickChange site-
directed mutagenesis (Agilent Technologies) according to the
manufacturer’s instructions and verified by sequencing using
ABI Prism BigDye Terminator version 3.1 cycle sequencing kit
(Applied Biosystems). GRP1-PH was amplified by PCR from
pGEX-4T3-GRP1-PH using primers flanked by BglII and SalI
restriction sites and subcloned into pEGFP-C2-NLS. All primers
are listed in Supplementary Table S1.
GST-tagged protein expression and purification
GST-PLCδ1-PH and GST-GRP1-PH were expressed and purified
as described previously [24]. GST-EBP1, full length (FL), N-
and C-terminal fragments, WT and mutants were transformed
into Escherichia coli BL21-RIL DE3 and bacterial cultures were
grown at 37 ◦C and further induced with 0.5 mM isopropyl-E-
D-thiogalactopyranoside for 3 h at 37 ◦C. Bacterial pellets were
resuspended in 50 mM Tris pH 7.5, 2 mM EDTA, 1 mM DTT
and 1x Sigma protease inhibitor cocktail, sonicated three times
for 30 s at 4 ◦C and centrifuged at 4400 g for 10 min at 4 ◦C. GST-
tagged proteins were purified with glutathione-agarose 4B beads
from an overnight pull down, eluted with 50 mM Tris pH 8.0,
100 mM NaCl, 0.5 mM DTT and 10 mM reduced glutathione,
and analysed by SDS/PAGE and Coomassie staining for purity.
For NMR studies, E.coli were grown in M9 minimal medium,
supplemented with 6 g/l Na2HPO4, 3 g/l KH2PO4, 0.5 g/l NaCl,
0.25 g/l MgSO4, 1 g/l 98%-enriched (15NH4)2SO4 and/or 4 g/l
13C6-glucose to produce 15N- and/or 13C-uniformly labelled GST-
C-terminal domain of EBP1. Further protein expression and
purification was performed using the same protocol as described
above.
Lipid overlay assays
Lipid overlay assay was carried out using PIP StripsTM (Echelon
Biosciences) spotted with 100 pmol of each of the 7 PPIns in
addition to other phospholipids, and PIP ArraysTM spotted with
1.56–100 pmol of PtdIns or each of the 7 PPIns. PIP stripsTM and
arrays were incubated with blocking buffer (3% fatty acid-free
BSA (Sigma A6003) in TBS-T (50 mM Tris pH 7.5, 150 mM
NaCl, 0.1% Tween-20) for 1 h at room temperature. PIP StripsTM
were incubated with 1.5 μg/ml GST-tagged protein or dialysed
neomycin extracts in the same buffer overnight at 4 ◦C. Detection
of GST-tagged proteins and EBP1 (from neomycin extracts) was
performed with an anti-GST-HRP conjugated antibody (Abcam,
ab3416, 1:50000) and an anti-EBP1 antibody (M. Squatrito,
1:800) respectively, both diluted in blocking buffer. PIP arraysTM
were incubated with anti-PtdIns(3,4,5)P3 (Echelon, #Z-P345b,
1:10000) followed by anti-mouse IgG-HRP (1:10000), both
diluted in blocking buffer made in PBS-T (137 mM NaCl,
2.68 mM KCl, 8 mM Na2HPO4, 1.8 mM KH2PO4, 0.1% Tween-
20). Six washes of 5 min each with TBS-T or PBS-T were
performed after incubations with protein and antibody. The
protein–lipid interactions were visualized using a west pico or
femto chemiluminescent substrate and a Bio-Rad ChemiDocTM
XRS + Imaging System from Bio-Rad and the ImageLabTM
Software Version 3.0.
Relative binding of EBP1 to the phospholipids was
quantified by densitometry using ImageJ software (http://rsb.info.
nih.gov/ij). The data were normalized to background signals for
each blot.
NMR spectroscopy
The NMR sample contained 0.14 mM uniformly 15N- and/or
13C-labelled GST-CTD-EBP1 in 50 mM Tris buffer S + 5.5
containing 100 mM NaCl, 0.5 mM 2-mercaptoethanol and 90%
H2O/10% D2O. NMR spectra were acquired at 298 K on a Bruker
Avance spectrometer operating at proton frequency of 600.13
MHz using the acquisition parameters provided in Supplementary
Table S2. The spectrometer was equipped with a TCI 5-mm
triple resonance cryo-probe with pulse field gradients along
the z-axis. Spectra were recorded and processed in TopSpin
2.1 (Bruker Biospin). 1H, 13C and 15N backbone resonance
assignments for the protein were determined using CARA
(Computer Aided Resonance Assignment) version 1.8.4.2 [56].
Secondary structure propensities (SSP) were calculated with the
Cα and Cβ chemical shifts as input into the SSP algorithm [57].
To monitor protein-lipid binding 1H–15N heteronuclear single
quantum coherence (HSQC) spectra acquired in the absence
and presence of 0.08 mM diC16-PtdIns(3,4,5)P3 or 0.33 mM
diC8-PtdIns(3,4,5)P3 (Echelon Biosciences) were subsequently
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compared and analysed. The peak intensities were measured in
CARA using peak-fitting algorithm [56]. The robustness of the
intensity values was tested by using different fit parameters and
the variation in the output did not exceed 2%.
Cell culture and transfection
MEL cells were cultured with DMEM supplemented with 10%
foetal bovine serum (FBS) and antibiotics (50000 units of both
penicillin and streptomycin) at 37 ◦C with 5% CO2. AU565
cells were cultured under the same conditions but in RPMI-1640
medium. For transfections, cells were plated in six-well plates
and transfected with 1–2 μg DNA and XtremeGene 9 (Roche)
at 3:1 ratio for 24 h. Treatment with the pan-PI3K inhibitor
LY294002 (10 μM) or DMSO (0.2% (v/v)) was performed 4 h
post-transfection.
Nuclear fractionation and neomycin extraction
Nuclei were isolated according to a method by Mukai et al.
[58] with some modifications. Cells were washed two times in
PBS and once briefly in buffer A (10 mM Hepes pH 7.9, 10 mM
KCl, 1.5 mM MgCl2, 340 mM sucrose, 10% glycerol). Cells
were resuspended in buffer A containing 0.1 % Triton X-100,
1 mM DTT, 5 μg/ml leupeptin and 5 μg/ml aprotinin, left to swell
for 5 min on ice and centrifuged at 1300 g for 5 min at 4 ◦C.
Nuclei were washed quickly with retention buffer (20 mM Tris
pH 7.5, 70 mM NaCl, 20 mM KCl, 5 mM MgCl2 and 3 mM CaCl2
[59]). Nuclei were incubated twice in retention buffer for 30 min
at room temperature, split into two equal fractions and further
incubated in the presence or absence of 5 mM neomycin (trisulfate
salt, Sigma N6386) for 30 min at room temperature. Samples
were centrifuged at 9600 g for 5 min at 4 ◦C and super-
natants were collected. For lipid overlay assays, neomycin
supernatants were dialysed twice against 20 mM HEPES pH 7.5,
150 mM NaCl, 5 mM EDTA and 0.1% NP-40.
SDS/PAGE and Western immunoblotting
Proteins were resolved by SDS/PAGE and transferred to
nitrocellulose membranes. Membranes were blocked with 5%
non-fat milk, incubated with primary antibodies overnight at
4 ◦C and with secondary antibodies conjugated to HRP for
1 h at room temperature. Protein detection was performed
by chemiluminescence using the SuperSignal West Pico
Chemiluminescent Substrate (Pierce) and imaged using the
Molecular Imager® ChemiDocTM XR + Imaging System and the
ImageLabTM Software Version 3.0 (Bio-Rad).
Immunostaining and microscopy
AU565 cells were seeded on 12 mm glass coverslips placed in
12-well plates and cultivated for 24 h before fixation. The cells
were washed two times in PBS, fixed in 3.7% paraformaldehyde
for 10 min at room temperature. Following fixation, cells were
washed three times with PBS, permeabilized with 0.25% Triton
X-100 in PBS pH 7.2 for 10 min at room temperature and blocked
with 5% goat serum in PBS containing 0.05 % Triton X-100
for 1 h at room temperature. Cells were incubated overnight at
4 ◦C with anti-EBP1 (abcam ab33613, 1:200, and antibody from
M. Squatrito, 1:800, o/n), anti-NPM (Zymed 32-5200, 1:1000,
1 h), anti-nucleolin (Cell Signaling 14574, 1:100, 1 h), anti-p110β
(abcam ab151549, 1:50, o/n), anti-PtdIns(3,4,5)P3 (Echelon,
1:200, o/n) diluted in blocking buffer, followed by incubation
with anti-mouse IgG antibody conjugated to Alexa-594 (1:200) or
Alexa-488 (1:400) (Life Technologies) diluted in blocking buffer
for 1 h at room temperature. Washes were performed with 0.05%
PBS-T after incubation with each antibody. The cover slips were
mounted in ProLong® Gold Antifade Reagent containing 4′,6-
diamidino-2-phenylindole (DAPI) (Life Technologies). Control
staining with secondary antibody alone under the same staining
and exposure conditions showed no unspecific staining. Images
were acquired with a Leica DMI6000B fluorescence microscope
using ×40 or ×100 objectives or with a Leica TCS SP5 confocal
laser scanning microscope using a 63×/1.4, oil immersion lens.
Images were processed with the Leica application suite v4.0 and
Adobe Photoshop CS5.
RESULTS
EBP1 binds directly to phosphoinositides
We have previously identified EBP1 as a potential PtdIns(4,5)P2-
binding protein by combining PtdIns(4,5)P2 pull down from
neomycin-displaced nuclear proteins and quantitative MS [24].
The peptides which identified EBP1 are shown in Supplementary
Figure S1 and include a peptide which only matches the long
p48 variant. We first validated that p48-EBP1 could be displaced
by neomycin from the nucleus by Western immunoblotting
analyses (Figure 1A). We next assessed EBP1 as a direct
PPIn-interacting protein by performing lipid overlay assays on
phospholipid-immobilized strips (Figure 1B) using recombinant
p48-GST-EBP1. As shown in Figure 1(C), GST-EBP1 bound to
several PPIn species including the three mono-phosphorylated
PPIns and PtdIns(3,5)P2. Binding to PtdIns(4,5)P2, PtdIns(3,4)P2,
phosphatidic acid (PA) and phosphatidylserine (PS) is weaker
and not always detected (Figures 1C and 1D). GST showed
no interaction by itself. Control binding experiments for
PtdIns(4,5)P2 and PtdIns(3,4,5)P3 were also performed using
specific probes, i.e. GST-fused PH domains of PLC-δ1 and GRP1
respectively. As shown in Figure 1(C), the PH domain of PLC-
δ1 bound strongly to PtdIns(4,5)P2, whereas very weak binding
was observed for PtdIns3P, Ptdins5P and PtdIns(3,5)P2. The PH
domain of GRP1 interacted strongly with PtdIns(3,4,5)P3 and very
weakly with both PtdIns(4,5)P2 and PtdIns(3,5)P2. Considering
that EBP1 interacts with most anionic phospholipids, we tested
the effect of increasing NaCl concentration on these interactions
(Figures 1E and 1F). Doubling the NaCl concentration had
overall little effect on interaction but binding to the three
mono-phosphorylated PPIns and PtdIns(3,5)P2 was essentially
the same as measured by retention of the protein to the strips,
although PA and PS binding was reduced. Adding 400 mM NaCl
nearly abolished all interaction detected except for PtdIns4P
and PtdIns(3,5)P2. These results suggest that the interactions
with PtdIns3P, PtdIns5P and particularly with PtdIns4P and
PtdIns(3,5)P2 have the highest affinity for the FL EBP1
protein.
EBP1 binds to PPIns via two lysine-rich PBRs
EBP1 does not harbour PPIn-binding modules, such as PH,
PX or FYVE domains [60], that could account for the
observed interactions. However, stretches of basic amino acids
denoted as PBRs [61] or KR-motifs following the sequence
K/R-(Xn = 3–7)-KXKK, have also been implicated in PPIn-binding
via electrostatic interactions [62]. Such basic amino acid stretches
have since then been identified in several nuclear proteins in
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence 4.0 (CC BY).





































































































Figure 1 EBP1 binds to phosphoinositides
(A) MEL nuclei were isolated, washed and incubated in retention buffer without ( − ) or with ( + ) 5 mM neomycin for 30 min at RT. Supernatants were analysed by Western immunoblotting.
(B) PIP strip schematic overview showing the positions of the spotted lipids (www.echelon-inc.com). LPA, lysophosphatidic acid; LPC, lysophosphatidylcholine; PI, phosphatidylinositol; PE,
phosphatidylethanolamine; PC, phosphatidylcholine; S1P, sphingosine-1-phosphate; PA, phosphatidic acid; PS, phosphatidylserine. (C) PIP strips incubated with recombinant GST-fused proteins
(EBP1 FL WT, PLC-δ1-PH and GRP1-PH domains) and detection of protein–lipid interactions using an anti-GST-HRP conjugated antibody. (D) Quantification of binding signal from four separate
experiments shown as means + S.D. of densitometry ratios related to background signal. (E) PIP strips incubated with GST-EBP1 FL in TBS-T containing 150–400 mM NaCl and detection of
protein–lipid interactions using an anti-GST-HRP conjugated antibody. (F) Quantification of binding signal from two separate experiments shown as means + S.D. of densitometry ratios (300/150)
each related to background signals.
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complex with PPIn [24] including the nuclear proteins ING2
[30], Pf1 [28], SAP30L [29], and more recently in BASP1 [43],
UHRF1 [63] and TAF3 [42] (Figure 2A). EBP1 has a KR-motif in
the unstructured C-terminal region (364RKTQKKKKKK373) [24],
named C-term PBR, as well as a reverse KR-motif situated on a
protruding loop of the N-terminal part (65KKEKEMKK72), named
N-term PBR (Figures 1A and 1B). These two PBRs are highly
conserved, suggesting a functional importance (Supplementary
Figure S2). Point mutations of three basic residues out of five to
alanines within the PBR of SAP30L (87KRKRK91 → 87KAAAK91)
led to a significant decrease in binding to monophosphorylated
PPIns [29]. In order to investigate if the C-terminal PBR-
motif of EBP1 played a similar role in PPIn-binding, four out
of six lysines were substituted to alanines in the FL GST-
EBP1, resulting in the following quadruple C-term PBR mutant
368KAAAAK373 (FL-C-K4A). FL-C- K4A was tested for its
PPIn-binding properties by lipid overlay assay in parallel with
the wild-type (WT) FL GST-EBP1. This mutant did not show
significant change in PPIn-binding compared with WT except
for a variable decrease in binding to PtdIns(3,5)P2 (results not
shown). A mutant was also produced in the N-terminal PBR
motif residing on the protruding loop (Figure 2B), resulting in the
FL-N-K2A mutant 65AAEKEMKK72. Again, this mutant did not
show any change in the PPIn-binding pattern compared with WT
(results not shown). These results suggested that both motifs may
act independently in binding to PPIns. An N-terminal fragment
(amino acids 1–351), harbouring the N-term PBR motif and a
C-terminal fragment (amino acids 352–394) containing the C-
term PBR, were therefore created (Figure 2C and Supplementary
Figure S3) and tested in lipid overlay assays (Figure 2D). As
shown in Figure 2(D) both fragments retained the ability to
bind to PPIns, including the three mono-phosphorylated PPIns
and PtdIns(3,5)P2 for both the N- and C-terminal fragments.
The C-terminal fragment was able to bind to the remaining
PPIns but with variable intensity. The C-K4A mutant abolished
PPIn-binding, when tested in the C-term construct (Figure 2D).
The N-K2A mutant showed a great decrease in binding when
tested in the N-term construct (results not shown) and binding
was completely blocked when an additional lysine at K68 was
substituted to alanine (Figure 2D). Finally, when the C-K4A and
N-K3A mutants were both introduced in the FL protein, PPIn
interaction was completely abolished.
Nucleolar localization of EBP1 is mediated predominantly by the
C-terminal PBR
EBP1 has previously been shown to localize in the nucleolus of
HeLa and NIH-3T3 cells [53] and we confirmed this finding in
the breast cancer cell line AU565 cells by co-immunostaining
EBP1 with the nucleolar protein NPM. As shown in Figure 3(A),
EBP1 was detected both in the cytoplasm, and in punctate
foci within NPM-stained nucleoli. The first 48 amino acids
in p48-EBP1 were previously shown to be necessary for its
nuclear targeting whereas the region spanning amino acids 301–
394 was shown to be responsible for its nucleolar localization
[53]. Using the nucleolar localization sequence detector (NoD
[64]), a nucleolar localization sequence (NoLS) was predicted
in EBP1 in amino acids 357–385, which lies within the region
previously found to be responsible for nucleolar targeting
(Figure 3B and Supplementary Figure S4A). This putative NoLS
is well conserved and, interestingly, contains the C-terminal PBR
(Figure 3B and Supplementary Figure S4B). We argued therefore
that this PPIn-binding motif could contribute to the localization
of EBP1 in the nucleolus. AU565 cells were transfected with
FL EGFP-tagged WT, C-K4A and N-K3A mutants as well as
the N-K3A/C-K4A double mutant and examined by fluorescence
microscopy (Figure 3C). In contrast with EGFP alone, which was
found in both the cytoplasm and nucleus, EGFP-EBP1 WT and
mutants exhibited overall three different patterns of localization
(Supplementary Figure S5). The different localization patterns
were quantified for WT and each of the mutants (Figure 3D).
The first pattern (pattern #1) is characterized by the appearance of
EBP1 in the cytoplasm, the peri-nuclear area and the nucleolus, as
reported previously [51,53]. This pattern was observed in 37% of
cells expressing WT-EBP1 but did not occur in any of the mutants
(Figures 3C and 3D). The second pattern (pattern #2) includes
either a restricted localization in the cytoplasm with an intense
peri-nuclear signal (pattern #2a, Supplementary Figure S5), or
a diffuse localization in both cytoplasm and nucleus (pattern
#2b, Supplementary Figure S5). Pattern #2 was dominant in cells
expressing WT (61%) or the N-K3A mutant (71%) but also
occurred in a lower proportion of cells expressing C-K4A (24%)
and the double mutant (30%) (Figure 3D). The third pattern
(pattern #3), which consists of a cytoplasmic and nucleolar-free
localization was mainly observed in cells expressing the C-K4A
mutant (76%) and the N-K3A/C-K4A double mutant (70%)
and less so for the N-K3A mutant (29 %) (Figures 3C and 3D).
Some differences were however observed among these mutants
for this pattern. The C-K4A mutant was not only excluded from
the nucleolus but also strongly retained in the rest of the nucleus
(pattern #3c Supplementary Figure S5, Figure 3C). In contrast,
the N-K3A mutant and double mutant, which were devoid of
nucleolar localization, did not allow the nuclear retention of
EBP1 (pattern #3d, Supplementary Figure S5, Figure 3C). The
protein levels of all three mutants were lower compared with WT,
and the N-K3A mutant had the lowest decrease compared with
the other two EBP1 mutants (Figure 3E). These results suggest
therefore that the C- and N-term PBRs contribute to the nucleolar
localization of EBP1, albeit in a different manner. The C-term
PBR has in addition nuclear export properties.
PtdIns(3,4,5)P3 is localized in the nucleoplasm and nucleolus
EBP1-p48 has previously been shown to bind to NPM [65].
Considering that NPM was also shown to be pulled down
in a complex with PtdIns(3,4,5)P3 from isolated nuclei [46],
and that we showed that the C-terminal PBR of EBP1
could bind to PtdIns(3,4,5)P3, at least among other PPIns
(Figure 2D), we argued that PtdIns(3,4,5)P3 could be found in
the nucleolus, in association with EBP1. Consequently, we used
the PtdIns(3,4,5)P3-specific probe GRP1-PH, fused it with NLS-
EGFP and examined its localization by immunofluorescence. In
contrast with NLS-EGFP, which was predominantly diffuse in the
nucleus, the NLS-EGFP-GRP1-PH was found in 81% of cells in
the nucleus and strongly in the nucleolus together with nucleolin
(Figures 4A and 4B). Furthermore, administration of the pan-
PI3K inhibitor LY 294002 significantly impaired the nucleolar
localization of NLS-EGFP-GRP1-PH by more than half (32 %).
We also examined the localization of both PtdIns(3,4,5)P3 and
the nucleolar protein nucleolin by immunostaining in AU565
cells using a protocol previously established to detect detergent-
resistant PPIns in the nucleus [18]. PtdIns(3,4,5)P3 was detected
in the cytoplasm, nucleoplasm and nucleolus together with
nucleolin (Figure 4D). The specificity of the anti-PtdIns(3,4,5)P3
antibody was validated firstly by lipid overlay assays using PIP
arrays (Figure 4C). Secondly, pre-incubation of the antibody
with different PPIns showed that nucleoplasmic and nucleolar
staining was abolished by the presence of PtdIns(3,4,5)P3 but
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N-term EBP1
N-WT WTC-WT




            C-term motif:
C-WT:   364RKTQKKKKKK373
C-K4A:  364RKTQKAAAAK373
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EBP1   355 KALLQSSAS-RKTQKKKKKKASKT
SAP30L  77   HKNFIQSVR-N-KRKRK-TS
Pf1    103 C-------TVR---RKKR-EQKKE
ING2   256 CRGDNEKTMDKSTEKTKKD--RRSR



















Figure 2 EBP1 harbours two lysine-rich PBRs required for PPIn interaction
(A) Alignment of the C-terminal lysine-rich PBR of EBP1 with other nuclear PIP-binding proteins. (B) 3D structure of EBP1 amino acids 1–361 and location of the N-terminal lysine-rich PBR loop
(pdb 2Q8K). (C) Representation of the recombinant GST-EBP1 FL, N-terminal (N-term) and C-terminal (C-term) constructs and the approximate locations of the two lysine-rich PBRs as well as their
mutants highlighted in red. (D) PIP strips were incubated with recombinant GST-EBP1 proteins (FL, N- and C-terminal), WT or the following lysine-rich PBR mutants, N-K3A (K65A–K66A–K68A),
C-K4A (K369A–K370A–K371A–K372A) and N-K3A/C-K4A combined mutant. Protein–lipid interactions were detected using an anti-GST-HRP conjugated antibody.
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Figure 3 EBP1 localizes to the nucleolus via its C-terminal lysine-rich PBR
(A) AU565 cells co-stained with anti-EBP1 and anti-NPM antibodies and imaged by confocal microscopy. 5 μmol scale bars. (B) Alignment of the putative NoLS sequence and the C-term K-rich
PBR of human EBP1. (C) AU565 cells transfected with EGFP-C2-EBP1 WT and mutant FL constructs, stained with anti-NPM and imaged by epifluorescence microscopy. Scale bars are all 10 μmol.
(D) Quantification of the localization patterns of EGFP-EBP1 WT and mutants from at least three different experiments + S.D. (E) Western immunoblotting of AU565 cell extracts obtained following
transfection with EGFP-C2-EBP1 WT and mutant FL constructs.
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Figure 4 PtdIns(3,4,5)P3 is localized in nucleoli
(A) AU565 cells transfected with NLS-EGFP or NLS-EGFP-GRP1-PH and incubated with 10 μmol LY-294002, stained with anti-nucleolin and imaged by epi-fluorescence. (B) Quantification
of the nucleolar localization of the NLS-EGFP-GRP1-PH from three different experiments + S.D. (C) PIP array spotted with 1.56–100 pmol of each of seven PPIn species incubated with an
anti-PtdIns(3,4,5)P3 and an anti-mouse-HRP conjugated antibody. (D) Confocal images of AU565 cells co-stained with anti-nucleolin and anti-PtdIns(3,4,5)P3 antibodies. (E) Confocal images of
AU565 co-stained with an anti-p110β and anti-NPM antibodies. Scale bars are all 5 μmol.
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Figure 5 EBP1 partially co-localizes with PtdIns(3,4,5)P3
(A) AU565 cells co-stained with anti-EBP1 and anti-PtdIns(3,4,5)P3 antibodies and imaged by confocal microscopy. (B) PIP strips were incubated with dialysed neomycin-displaced protein extracts
and protein–lipid interaction was detected with only anti-rabbit-HRP antibody (-) or with anti-EBP1 and anti-rabbit-HRP antibodies ( + ). (C) Dialysed neomycin-displaced protein extracts (20 μg)
resolved by SDS/PAGE and immunoblotted with an anti-EBP1 antibody.
not by PtdIns3P and PtdIns(3,4)P2 (Supplementary Figure S6).
Furthermore, the localization of p110β, one of the class IA
phosphoinositide 3-kinase (PI3K) catalytic subunits producing
PtdIns(3,4,5)P3, has previously been reported to be present in
the nucleus [66]. Following immunostaining of AU565 cells,
we detected p110β in the cytoplasm and strongly in the
nucleolus together with NPM (Figure 4E). In summary, these
results show the specificity of the anti-PtdIns(3,4,5)P3 antibody
utilized, and that the nucleolar sites detected by the antibody
are PtdIns(3,4,5)P3. The presence of p110β in nuclei further
substantiates the existence of nucleolar PtdIns(3,4,5)P3.
EBP1 co-localizes partially with PtdIns(3,4,5)P3 in the nucleolus
Considering that EBP1 and PtdIns(3,4,5)P3 were independently
detected in nucleoli, we sought to determine if they co-localized
by immunofluorescence. Using confocal microscopy, EBP1 was
found to partially co-localize with PtdIns(3,4,5)P3 within nucleoli,
suggesting therefore a potential association (Figure 5A). Binding
of recombinant EBP1 to PtdIns(3,4,5)P3 is however weaker
compared with binding to other PPIns (Figures 1D and 2D) and
we considered that endogenous EBP1 may bind to PPIns in a
different profile. To further examine the PPIn-binding properties
of nuclear EBP1, we performed lipid overlay assays using
neomycin-displaced protein extracts obtained from AU565 nuclei
followed by detection with an anti-EBP1 antibody (Figure 5B).
The pattern of interaction was similar to the recombinant protein,
and in particular to the C-terminal fragment, and showed binding
to most PPIns including PtdIns(3,4,5)P3. These extracts were
also resolved by Western immunoblotting to demonstrate the
specificity of the anti-EBP1 antibody (Figure 5C). Taken together,
these results show that endogenous EBP1 and PtdIns(3,4,5)P3 can
also associate in nucleoli.
NMR analyses of EBP1–PtdIns(3,4,5)P3 interaction
To establish further the interaction of EBP1 with PtdIns(3,4,5)P3
at the molecular level, high resolution NMR was used. The C-
term PBR was examined since we have shown that it binds
better to PtdIns(3,4,5)P3 in lipid overlay assays and it strongly
affects the nucleolar localization of EBP1, where EBP1 and
PtdIns(3,4,5)P3 co-localize. Figure 6(A) shows a typical 1H-
15N HSQC fingerprint spectrum of the 15N isotopically labelled
GST-C-terminal fragment of EBP1 (see Supplementary Figure
S7 for more details). In order to first assign each amide signal
to a specific residue in the protein, standard NMR experiments
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence 4.0 (CC BY).


























































































































Figure 6 NMR characterization of the EBP1 C-terminal domain interacting with PtdIns(3,4,5)P3
(A) 1H–15N HSQC fingerprint spectrum of the GST-C-terminal EBP1 alone (blue). Assigned NH cross-peaks are marked in one-letter amino acid code and sequence number. Residues originating
from the linker sequence positioned between the GST tag and the target sequence of EBP1 are labelled in green and marked with a star. Amino acid numbering for the linker region preceding the CTD
is maintained according to the EBP1 sequence. (B) SSP score calculated using combined Cα and Cβ chemical shift values of the assigned EBP1 residues. Residues prone to form α-helix have a
positive score, residues with a negative SSP score are prone to occupy β-sheet or extended loops. Residues in fully formed α-helixes and β-sheets are given the score of 1 and -1 respectively.
(C) Superimposition of the 1H–15N HSQC spectra obtained for the C-terminal EBP1 in the absence (blue) and in the presence of diC16-PtdIns(3,4,5)P3 (red). (D) Signal intensity change upon
addition of PtdIns(3,4,5)P3 calculated for EBP1 residues based on the results presented in panel C. (E) Superimposition of the 1H–15N HSQC spectra obtained for the C-terminal EBP1 in the absence
(blue) and in the presence of diC8-PtdIns(3,4,5)P3 (red). (F) Signal intensity change upon addition of PtdIns(3,4,5)P3 calculated for EBP1 residues based on the results presented in panel E. Green
coloured bars indicate lysines from the C-terminal PBR.
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were performed to detect 13C chemical shifts and sequential
connectivities. Heteronuclear 3D NMR experiments led to the
chemical shift assignment of 1H, 15N and 13C nuclei for 37 out
of 43 (86%) residues in the C-terminal fragment of EBP1.
Ala352, Glu353, Leu354, as well as the following residues from
the PBR, Lys369, Lys370, Lys371, were not assigned due to signal
broadening beyond detection, which could be attributed to the
intermediate solvent or conformational exchange rates of the
protein. Altogether, the number of amide proton cross-peaks, as
well as nearly complete assignment of the protein, demonstrated
that the observed signals originated almost exclusively from the
target protein and not from GST (see also Supplementary Figure
S7). The narrow signal dispersion of the spectrum, observed
for the backbone amide protons (cross-peaks positioned within
8.7–7.7 ppm range in the 1H dimension), indicates an overall
disordered state of the protein. For proteins without a stable,
folded structure, chemical shifts are essential parameters encoding
local conformational propensities of the protein in solution
[67,68]. To predict these propensities for the C-terminal fragment
of EBP1, the obtained chemical shifts were processed to evaluate
its secondary structure propensity (SSP) score using the SSP
program [57]. Figure 6(B) illustrates the SSP score calculated
for each assigned residue of the C-terminal fragment based on the
combined Cα and Cβ chemical shifts. According to the SSP data,
the C-terminal fragment has a largely disordered conformation
except for the N-terminal region of the fragment (aa 355–365)
showing a slight propensity to form an α-helix, consistently with
the X-ray data for this region [69]. We next mapped the interaction
site of the C-terminal EBP1 with either diC16- (Figure 6C)
or diC8-PtdIns(3,4,5)P3 (Figure 6E). Addition of either long or
short acyl chain PtdIns(3,4,5)P3 resulted in a decrease in signal
intensity for all cross-peaks (Figures 6D and 6F), which could
be due to resonance broadening caused by the presence of the
lipid. Nevertheless, differences in signal ratios were observed
across the C-term PBR. The most pronounced signal intensity
changes were observed when diC16-PtdIns(3,4,5)P3 was added, in
particular for residues located in the N-terminus part and the PBR
(Lys355, Ala356, Leu357, Leu358, Gln359, Ala362, Ser363, Lys365, Thr366,
Gln367, Lys368, as well as Lys372, Lys373, Ala374, Ser375, Lys376, with
a ratio <0.2, and for Ser360, Ser361 and Arg364 with a ratio < 0.4).
Similar effects were observed for the PBR residues when diC8-
PtdIns(3,4,5)P3 was added, but less intensity changes were overall
detected in residues in the N-terminal part. These results validate
that protein–lipid contacts involve most importantly electrostatic
forces between lysines and phosphates. Hydrophobic interactions
between nonpolar N-terminal residues and with long acyl chains,
notably in the region covered by 356ALL358, may also be involved,
particularly with long hydrocarbon chains.
A tumour-associated mutant within the C-terminal PBR affects
EBP1 nucleolar localization
EBP1 has previously been implicated to have tumour suppressor
properties in different cancer types including salivary adenoid
cystic and hepatocellular carcinoma (HCC), as well as prostate
and breast cancer [70–73]. Consistently, the levels of EBP1
have been shown to be down-regulated in prostate cancer
and HCC while its overexpression induced a decrease in cell
proliferation in breast, thyroid and HCC cancer cells [70,73,74].
In contrast, recent studies have shown opposite role for EBP1 in
cell proliferation since knockout mice present growth retardation
[75] and overexpression induces proliferation in muscle stem
cells [76]. PA2G4, the gene encoding EBP1, is mutated at a
very low frequency (0.24 % in all tumours). A mutation was
however identified in the C-term PBR, i.e. K372N (Figure 7A),
in an endometrial tumour sample. We therefore introduced this
point mutation in EGFP-EBP FL or GST-EBP1 C-terminal
constructs and examined its effect on EBP1 compartmentalization
(Figure 7B) and PPIn binding (Figures 7C and 7D and
Supplementary Figure S8). The K372N point mutant exhibited
a more pronounced pattern #2 (cytoplasmic with either diffuse
or no signal within the nucleus) in 93% of K372N-expressing
cells compared with 61% in WT. Concomitantly, a decrease in
pattern #1 (cytoplasmic, peri-nuclear and nucleolar) was observed
with 7% in K372N-expressing cells, compared with 38% in
WT. In contrast with the C-K4A mutant, this point mutation
was however not sufficient to affect nuclear export as it did not
lead to the retention of EBP1 in the nucleoplasm. In addition,
PPIn interaction was overall only slightly reduced when the
mutation was introduced in the C- terminal EBP1 construct but
interestingly a stronger decrease in interaction was observed for
PtdIns(3,4,5)P3, as well as for PtdIns(3,4)P2 and PA (Figures 7C
and 7D). In summary, the K372N point mutant has an intermediate
localization and PPIn-binding properties compared with the
quadruple C-K4A mutant. The occurrence of this mutation in
cancer may however point to the importance of this PBR in EBP1
function.
DISCUSSION
We have previously reported that short motifs consisting
of basic residues or PBRs following the sequence motif
K/R-(Xn = 3-7)-K-X-K/R-K/R were implicated in PPIn-binding
of nuclear proteins, suggesting a mode of interaction for PPIn-
interacting proteins localized in the nucleus [24]. In the present
study, we have identified two PBRs involved in the interaction
of EBP1 with PPIns via lysine residues. The N-term PBR
lies within a protruding loop although the C-term PBR is part
of an unstructured sequences described by Monie et al. [77].
The two PBRs demonstrate the same profile of interaction
with PPIns including the three mono-phosphorylated species
and PtdIns(3,5)P2. In addition the C-terminal PBR was more
promiscuous and interacted with all the other PPIns albeit more
weakly. This pattern of interaction is consistent with other studies
showing the importance of PBRs for PPIn binding in other
nuclear proteins such as ING2 [30], Pf1 [28], SAP30L [29],
and more recently UHRF1 [63] and TAF3 [42]. In particular,
mono-phosphorylated PPIns interact with SAP30L, Pf1, TAF3
and ING2 whereas PtdIns(3,5)P2 interacts with Pf1 and TAF3.
The consistency of the pattern of interaction of these PBRs
with certain PPIns is rather interesting and may hence point to
specificity due to the position of the phosphate on the inositol
ring for short basic motifs. Clusters of basic residues in PBRs
may hence preferentially accommodate interaction with either one
phosphate or PtdIns(3,5)P2 with sufficiently spaced phosphates.
Interestingly, SAP30L binds to mono-phosphorylated PPIns via
a stretch of three basic residues within its PBR which also
functions as an NLS adjacent to its DNA binding domain. The
C-terminal PBR of EBP1, which contains six adjacent lysines,
binds more extensively to PPIns and includes in addition the
other bis-phosphorylated as well as PtdIns(3,4,5)P3. The higher
number of lysines in this motif may hence offer more binding
probabilities and alternatives to several PPIns with differently
spaced phosphates on the inositol ring, at least in vitro.
The two PBRs may act independently and may provide different
cellular functions to EBP1. Considering that PPIns are known to
target proteins to different sub-cellular localizations, the two PBRs
may regulate the different cellular locations of EBP1 allowing for
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Figure 7 The tumour-associated EBP1 mutant K372N prevents its nucleolar localization
(A) Alignment of the WT C-terminal K-rich motif with the K372N mutant. (B) AU565 cells were transfected with the EGFP-C2-EBP1 K372N mutant FL construct, stained with anti-NPM and imaged
by epifluorescence microscopy (5 μmol scale bar). (C) PIP strips were incubated with the C-terminal domain GST-EBP1 WT and K372N proteins and protein–lipid interactions were detected using
an anti-GST-HRP conjugated antibody. (D) Quantification of binding signal as assessed in (C) from three separate experiments shown as means + S.D. of densitometry ratios of K372N/WT.
potential roles in the nucleolus and cytoplasm bound to ribosomes
[78]. We showed that the mutated N-terminal PBR restricted
EBP1 mostly to the cytoplasm and exhibited either little or a
diffuse nuclear signal in the majority of cells. The N-terminal
PBR may hence cooperate with the first 48 amino acids, including
the two lysines K20 and K22, shown previously to be necessary
for the nuclear localization of EBP1 [53]. The C-terminal PBR is
clearly important for the nucleolar localization of EBP1, and the
sequestration of the C-terminal PBR mutant in the nucleoplasm
coincident with its nucleolar exclusion suggest that this PBR also
plays a role in nuclear export of EBP1. Considering that the first
48 amino acids in EBP1 are critical for nuclear targeting [53],
the C-terminal PBR mutant is therefore able to reach the nucleus
but is however unable to be retained in the nucleolus. Another
nuclear protein, SAP30L, was shown to harbour a NoLS, located
C-terminal of its NLS, and to contribute to PPIn interaction
in addition to the NLS/PBR described previously [29]. The
NoLS in SAP30L consists of the following polybasic sequence
120RRYKRHYK127 and when all these residues were mutated to
alanines, SAP30L was excluded from the nucleolus but retained
in the nucleus [79], which is consistent with the behaviour of the
C-terminal PBR of EBP1. These studies raise the possibility of
multi functions for NoLS beyond nucleolar targeting, including
nuclear export as well as PPIn interaction.
The importance of the C-term PBR in the localization of
EBP1 is highlighted by the occurrence of a mutation in
endometrial cancer, K372N, which we have demonstrated to be
important in both PPIn interaction and nucleolar localization.
The importance of EBP1 compartmentalization in cancer takes
precedence in salivary cancer in which EBP1 is sequestered in
the cytoplasm in tumour areas whereas adjacent normal cells
localize EBP1 in both the cytoplasm and nucleus [80]. Sub-
nuclear details could however not be identified in the present study
to distinguish nucleolar staining. The sub-cellular localization
of EBP1 has moreover been suggested to be important for its
function and its nucleolar localization correlates with its role
in cell proliferation suppression [53]. Based on this, we also
suggest that the C-terminal PBR is involved in regulating the
cellular function of EBP1 by inducing changes in its sub-cellular
localization. Cancer cells may hence benefit from targeting the
C-terminal motif to alter the sub-cellular localization of EBP1
and perhaps more specifically by preventing EBP1 from entering
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the nucleolus. The role of EBP1 in the nucleolus remains to be
identified.
The molecular mode of retention of EBP1 in the nucleolus
is not clear but it is tempting to suggest that PtdIns(3,4,5)P3
interaction could play a role. Firstly, EBP1 association with
PtdIns(3,4,5)P3 was demonstrated in several ways: (1) the C-
term PBR binds to this PPIn species in vitro, as shown by lipid
overlay assays and NMR analyses, (2) endogenous nuclear EBP1
has binding capacity as shown by lipid overlay assays. Secondly,
partial co-localization of endogenous EBP1 with PtdIns(3,4,5)P3
within the nucleolus was observed, and this could be consistent
with a functional association. In addition, NMR studies revealed
that other residues located N-terminal of the PBR, including
the nonpolar 356ALL358 motif, made contact with PtdIns(3,4,5)P3
containing 16-carbon but not 8-carbon acyl chains. This would
suggest that the acyl chains contribute to the interaction together
with the head group. The participation of acyl chains in protein–
PPIn interaction is a mechanism that has previously been
suggested in several nuclear proteins identified to bind diC16-
PtdIns(3,4,5)P3 without the involvement of structured PI-binding
domain [27]. Thus, the identification of nuclear proteins which can
potentially accommodate the acyl chains of PPIns may provide
an explanation for the presence of PPIns in the non-membranous
environment of the nucleus and notably the nucleolus.
The presence of PtdIns(3,4,5)P3 in the nucleus has been
reported previously [16] and in particular in cells treated with
γ -irradiation [81] but the presence of this PPIn and the PI3K
catalytic subunit p110β in the nucleolus is reported for the first
time in the present study. A minor pool of nuclear PtdIns(4,5)P2
has previously been detected in the nucleolus of asynchronously
growing cells [18,82–84], which could hence be the source of
PtdIns(3,4,5)P3 production in this nuclear site. We have initially
identified EBP1 as a potential PtdIns(4,5)P2-binding protein
by pull down assay and mass spectrometry [24] and we have
shown in the present study that the C-terminal PBR of EBP1
can bind directly to both PtdIns(4,5)P2 and PtdIns(3,4,5)P3, the
two PPIns found to be present in the nucleolus. EBP1 may
therefore associate with PtdIns(4,5)P2 as well as PtdIns(3,4,5)P3
in this nuclear site. We observed that the pattern of detection
of nucleolar PtdIns(3,4,5)P3 varies in asynchronous AU565
(Figure 4C) and HeLa (results not shown) cells and can consist
of either a punctate and intense signal within nucleoli or a more
diffuse distribution in both the nucleoplasm and nucleolus. We
suggest therefore that EBP1 may associate differentially with
PtdIns(3,4,5)P3 or PtdIns(4,5)P2 under certain conditions of the
cell cycle. Consistently p110β has been previously reported to be
active during G1 to S phase transition of the cell cycle [85]. We
suggest therefore that changes in p110β activity could explain
the differential pattern of PtdIns(3,4,5)P3 in the nucleolus and
nucleoplasm and regulate the function of EBP1 and we are
currently pursuing this line of study.
Although the localization of EBP1 in the nucleolus can be due
to the interaction of its C-terminal PBR with PtdIns(3,4,5)P3,
another mode of retention of EBP1 is possible via rRNA-
interaction. The C-terminal region of EBP1 spanning amino
acids 361–394 was shown to be necessary for RNA interaction
[77], including the processed rRNA species 18S, 28S and 5.8S
[53]. This region comprises the C-terminal PBR described in the
present study and the lysines present within the PBR shown to be
involved in both nucleolar retention and PPIn interaction could
be responsible for RNA binding via electrostatic interactions.
Considering that this PBR is responsible for both PPIn interaction
and nucleolar retention and is implicated in nucleic acid binding,
we would suggest that PtdIns(3,4,5)P3 and rRNA compete for
binding to the C-terminal PBR. This scenario has indeed been
reported for the HIV-1 viral protein Gag where binding of RNA
to a highly basic region was demonstrated as a mechanism to
prevent PtdIns(4,5)P2-mediated binding to the plasma membrane
[86]. In addition, PtdIns(3,4,5)P3 interacts with NPM via lysine
residues [46], which are part of a basic, intrinsic disordered region
involved in RNA interaction [87]. Finally, PtdIns(3,4,5)P3 binds
ALY, a protein regulating mRNA export via basic residues [35],
and this interaction contributes to ALY-mediated recognition of
specific mRNA transcripts for their nuclear export [37]. In light
of our results obtained with the C-term PBR of EBP1 and studies
in NPM and ALY, it is tempting to suggest that PtdIns(3,4,5)P3
may regulate protein–RNA interaction utilizing basic motifs in
disordered regions which have dual functions in PPIn and RNA
interaction.
In conclusion, we have shown that the PBRs identified
in EBP1 have a dual function as they contribute to PPIn
interaction, potentially via electrostatic interactions, as well as
nucleolar localization. Considering that sub-cellular localization
often correlates with function, PBRs may provide a molecular
mechanism allowing EBP1 to switch between different sub-
cellular compartments and functions due to their interaction with
PPIns. In addition, this is the first report providing evidence of the
presence of PtdIns(3,4,5)P3 as well as the class I PI3K catalytic
subunit p110β in the nucleolus. EBP1 binds PtdIns(3,4,5)P3 and
this association is detected in the nucleolus. Our data imply novel
regulation of nucleolar functions by PtdIns(3,4,5)P3, which are
lines of research that we are currently pursuing.
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Aurélia Lewis conceived and coordinated the study and wrote the paper. Thomas Karlsson
performed and analysed the experiments shown in Figures 1, 2 and 7(C), and wrote part
of the paper. Altanchimeg Altankhuyag performed the experiments shown in Figures 3,
4(C)–4(E), 5, 7(B), Supplementary Figures S5 and S6. Olena Dobrovolska designed and
performed the experiments in Figure 6 and Supplementary Figure S7 and wrote parts of
the paper. Diana Turcu performed and analysed the experiments in Figures 4(A) and 4(B)
and edited the paper. All authors reviewed the results and approved the final version of the
manuscript.
ACKNOWLEDGEMENTS
We thank Øyvind Halskau (University of Bergen) for his help in NMR acquisitions and
useful discussions.
FUNDING
This work was supported by the Norwegian Cancer Society [grant number 2183087]; the
University of Bergen; and the Nansen fund [grant number 45549].
REFERENCES
1 Albi, E., Cataldi, S., Rossi, G. and Magni, M.V. (2003) A possible role of
cholesterol-sphingomyelin/phosphatidylcholine in nuclear matrix during rat liver
regeneration. J. Hepatol. 38, 623–628 CrossRef PubMed
2 Hunt, A.N. (2006) Dynamic lipidomics of the nucleus. J. Cell. Biochem. 97, 244–251
CrossRef PubMed
3 Postle, A.D., Wilton, D.C., Hunt, A.N. and Attard, G.S. (2007) Probing phospholipid
dynamics by electrospray ionisation mass spectrometry. Prog. Lipid Res. 46, 200–224
CrossRef PubMed
4 Michell, R.H., Heath, V.L., Lemmon, M.A. and Dove, S.K. (2006) Phosphatidylinositol
3,5- bisphosphate: metabolism and cellular functions. Trends Biochem. Sci. 31, 52–63
CrossRef PubMed
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence 4.0 (CC BY).
2046 T. Karlsson and others
5 Barlow, C.A., Laishram, R.S. and Anderson, R.A. (2010) Nuclear phosphoinositides: a
signaling enigma wrapped in a compartmental conundrum. Trends Cell Biol. 20, 25–35
CrossRef PubMed
6 Fiume, R., Keune, W.J., Faenza, I., Bultsma, Y., Ramazzotti, G., Jones, D.R., Martelli, A.M.,
Somner, L., Follo, M.Y., Divecha, N. and Cocco, L. (2012) Nuclear phosphoinositides:
location, regulation and function. Subcell. Biochem. 59, 335–361 CrossRef PubMed
7 Schramp, M., Hedman, A., Li, W., Tan, X. and Anderson, R. (2012) PIP kinases from the
cell membrane to the nucleus. Subcell. Biochem. 58, 25–59 CrossRef PubMed
8 Shah, Z.H., Jones, D.R., Sommer, L., Foulger, R., Bultsma, Y., D’Santos, C. and Divecha,
N. (2013) Nuclear phosphoinositides and their impact on nuclear functions. FEBS J. 280,
6295–6310 CrossRef PubMed
9 Cocco, L., Gilmour, R.S., Ognibene, A., Letcher, A.J., Manzoli, F.A. and Irvine, R.F. (1987)
Synthesis of polyphosphoinositides in nuclei of Friend cells. Evidence for
polyphosphoinositide metabolism inside the nucleus which changes with cell
differentiation. Biochem. J. 248, 765–770 CrossRef PubMed
10 Divecha, N., Banfic, H. and Irvine, R.F. (1991) The polyphosphoinositide cycle exists in
the nuclei of Swiss 3T3 cells under the control of a receptor (for IGF-I) in the plasma
membrane, and stimulation of the cycle increases nuclear diacylglycerol and apparently
induces translocation of protein kinase C to the nucleus. EMBO J. 10, 3207–3214
PubMed
11 Vann, L.R., Wooding, F.B., Irvine, R.F. and Divecha, N. (1997) Metabolism and possible
compartmentalization of inositol lipids in isolated rat-liver nuclei. Biochem. J. 327 Pt 2,
569–576 CrossRef PubMed
12 Clarke, J.H., Letcher, A.J., D’Santos, C.S., Halstead, J.R., Irvine, R.F. and Divecha, N.
(2001) Inositol lipids are regulated during cell cycle progression in the nuclei of murine
erythroleukaemia cells. Biochem. J. 357, 905–910 CrossRef PubMed
13 Jones, D.R., Bultsma, Y., Keune, W.J., Halstead, J.R., Elouarrat, D., Mohammed, S., Heck,
A.J., D’Santos, C.S. and Divecha, N. (2006) Nuclear PtdIns5P as a transducer of stress
signaling: an in vivo role for PIP4Kbeta. Mol. Cell 23, 685–695 CrossRef PubMed
14 Sarkes, D. and Rameh, L.E. (2010) A novel HPLC-based approach makes possible the
spatial characterization of cellular PtdIns5P and other phosphoinositides. Biochem. J.
428, 375–384 CrossRef PubMed
15 Gillooly, D.J., Morrow, I.C., Lindsay, M., Gould, R., Bryant, N.J., Gaullier, J.M., Parton,
R.G. and Stenmark, H. (2000) Localization of phosphatidylinositol 3-phosphate in yeast
and mammalian cells. EMBO J. 19, 4577–4588 CrossRef PubMed
16 Lindsay, Y., McCoull, D., Davidson, L., Leslie, N., Fairservice, A., Gray, A., Lucocq, J. and
Downes, C. (2006) Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear
pool that is insensitive to PTEN expression. J. Cell Sci. 119, 5160–5168
CrossRef PubMed
17 Boronenkov, I.V., Loijens, J.C., Umeda, M. and Anderson, R.A. (1998) Phosphoinositide
signaling pathways in nuclei are associated with nuclear speckles containing pre-mRNA
processing factors. Mol. Biol. Cell 9, 3547–3560 CrossRef PubMed
18 Osborne, S.L., Thomas, C.L., Gschmeissner, S. and Schiavo, G. (2001) Nuclear
PtdIns(4,5)P2 assembles in a mitotically regulated particle involved in pre-mRNA
splicing. J. Cell Sci. 114, 2501–2511 PubMed
19 Watt, S.A., Kular, G., Fleming, I.N., Downes, C.P. and Lucocq, J.M. (2002) Subcellular
localization of phosphatidylinositol 4,5-bisphosphate using the pleckstrin homology
domain of phospholipase C delta1. Biochem. J. 363, 657–666 CrossRef PubMed
20 Kwon, I.S., Lee, K.H., Choi, J.W. and Ahn, J.Y. (2010) PI(3,4,5)P3 regulates the interaction
between Akt and B23 in the nucleus. BMB Rep. 43, 127–132 CrossRef PubMed
21 Okada, M. and Ye, K. (2009) Nuclear phosphoinositide signaling regulates messenger
RNA export. RNA Biol. 6, 12–16 CrossRef PubMed
22 Martelli, A.M., Ognibene, A., Buontempo, F., Fini, M., Bressanin, D., Goto, K., McCubrey,
J.A., Cocco, L. and Evangelisti, C. (2011) Nuclear phosphoinositides and their roles in
cell biology and disease. Crit. Rev. Biochem. Mol. Biol. 46, 436–457 CrossRef PubMed
23 Viiri, K., Maki, M. and Lohi, O. (2012) Phosphoinositides as regulators of
protein-chromatin interactions. Sci. Signal. 5, pe19 CrossRef PubMed
24 Lewis, A.E., Sommer, L., Arntzen, M.O., Strahm, Y., Morrice, N.A., Divecha, N. and
D’Santos, C.S. (2011) Identification of nuclear phosphatidylinositol
4,5-bisphosphate-interacting proteins by neomycin extraction. Mol. Cell Proteomics 10,
M110.003376 CrossRef PubMed
25 Musille, P.M., Kohn, J.A. and Ortlund, E.A. (2013) Phospholipid-driven gene regulation.
FEBS Lett. 587, 1238–1246 CrossRef PubMed
26 Di Lello, P., Nguyen, B.D., Jones, T.N., Potempa, K., Kobor, M.S., Legault, P. and
Omichinski, J.G. (2005) NMR structure of the amino-terminal domain from the Tfb1
subunit of TFIIH and characterization of its phosphoinositide and VP16 binding sites.
Biochemistry 44, 7678–7686 CrossRef PubMed
27 Bidlingmaier, S., Wang, Y., Liu, Y., Zhang, N. and Liu, B. (2011) Comprehensive analysis
of yeast surface displayed cDNA library selection outputs by exon microarray to identify
novel protein-ligand interactions. Mol. Cell Proteomics 10, M110.005116
CrossRef PubMed
28 Kaadige, M.R. and Ayer, D.E. (2006) The polybasic region that follows the plant
homeodomain zinc finger 1 of Pf1 is necessary and sufficient for specific
phosphoinositide binding. J. Biol. Chem. 281, 28831–28836 CrossRef PubMed
29 Viiri, K.M., Janis, J., Siggers, T., Heinonen, T.Y., Valjakka, J., Bulyk, M.L., Maki, M. and
Lohi, O. (2009) DNA-binding and -bending activities of SAP30L and SAP30 are mediated
by a zinc-dependent module and monophosphoinositides. Mol. Cell Biol. 29, 342–356
CrossRef PubMed
30 Gozani, O., Karuman, P., Jones, D.R., Ivanov, D., Cha, J., Lugovskoy, A.A., Baird, C.L.,
Zhu, H., Field, S.J., Lessnick, S.L. et al. (2003) The PHD finger of the
chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell
114, 99–111 CrossRef PubMed
31 Huang, W., Zhang, H., Davrazou, F., Kutateladze, T.G., Shi, X., Gozani, O. and Prestwich,
G.D. (2007) Stabilized phosphatidylinositol-5-phosphate analogues as ligands for the
nuclear protein ING2: chemistry, biology, and molecular modeling. J. Am. Chem. Soc.
129, 6498–6506 CrossRef PubMed
32 Zhao, K., Wang, W., Rando, O.J., Xue, Y., Swiderek, K., Kuo, A. and Crabtree, G.R. (1998)
Rapid and phosphoinositol-dependent binding of the SWI/SNF-like BAF complex to
chromatin after T lymphocyte receptor signaling. Cell 95, 625–636 CrossRef PubMed
33 Rando, O.J., Zhao, K., Janmey, P. and Crabtree, G.R. (2002)
Phosphatidylinositol-dependent actin filament binding by the SWI/SNF-like BAF
chromatin remodeling complex. Proc. Natl. Acad. Sci. U.S.A. 99, 2824–2829
CrossRef PubMed
34 Mazzotti, G., Zini, N., Rizzi, E., Rizzoli, R., Galanzi, A., Ognibene, A., Santi, S., Matteucci,
A., Martelli, A.M. and Maraldi, N.M. (1995) Immunocytochemical detection of
phosphatidylinositol 4,5-bisphosphate localization sites within the nucleus. J.
Histochem. Cytochem. 43, 181–191 CrossRef PubMed
35 Okada, M., Jang, S.W. and Ye, K. (2008) Akt phosphorylation and nuclear
phosphoinositide association mediate mRNA export and cell proliferation activities by
ALY. Proc. Natl. Acad. Sci. U.S.A. 105, 8649–8654 CrossRef PubMed
36 Mellman, D.L., Gonzales, M.L., Song, C., Barlow, C.A., Wang, P., Kendziorski, C. and
Anderson, R.A. (2008) A PtdIns4,5P2-regulated nuclear poly(A) polymerase controls
expression of select mRNAs. Nature 451, 1013–1017 CrossRef PubMed
37 Wickramasinghe, V.O., Savill, J.M., Chavali, S., Jonsdottir, A.B., Rajendra, E., Gruner, T.,
Laskey, R.A., Babu, M.M. and Venkitaraman, A.R. (2013) Human inositol polyphosphate
multikinase regulates transcript- selective nuclear mRNA export to preserve genome
integrity. Mol. Cell 51, 737–750 CrossRef PubMed
38 Krylova, I.N., Sablin, E.P., Moore, J., Xu, R.X., Waitt, G.M., MacKay, J.A., Juzumiene, D.,
Bynum, J.M., Madauss, K., Montana, V. et al. (2005) Structural analyses reveal
phosphatidyl inositols as ligands for the NR5 orphan receptors SF-1 and LRH-1. Cell
120, 343–355 CrossRef PubMed
39 Blind, R.D., Suzawa, M. and Ingraham, H.A. (2012) Direct modification and activation of a
nuclear receptor-PIP2 complex by the inositol lipid kinase IPMK. Sci. Signal. 5, ra44
CrossRef PubMed
40 Blind, R.D., Sablin, E.P., Kuchenbecker, K.M., Chiu, H.J., Deacon, A.M., Das, D.,
Fletterick, R.J. and Ingraham, H.A. (2014) The signaling phospholipid PIP3 creates a new
interaction surface on the nuclear receptor SF-1. Proc. Natl. Acad. Sci. U.S.A. 111,
15054–15059 CrossRef PubMed
41 Sablin, E.P., Blind, R.D., Uthayaruban, R., Chiu, H.J., Deacon, A.M., Das, D., Ingraham,
H.A. and Fletterick, R.J. (2015) Structure of liver receptor homolog-1 (NR5A2) with PIP3
hormone bound in the ligand binding pocket. J. Struct. Biol. 192, 342–348
CrossRef PubMed
42 Stijf-Bultsma, Y., Sommer, L., Tauber, M., Baalbaki, M., Giardoglou, P., Jones, D.R.,
Gelato, K.A., van Pelt, J., Shah, Z., Rahnamoun, H. et al. (2015) The basal transcription
complex component TAF3 transduces changes in nuclear phosphoinositides into
transcriptional output. Mol. Cell 58, 453–467 CrossRef PubMed
43 Toska, E., Campbell, H.A., Shandilya, J., Goodfellow, S.J., Shore, P., Medler, K.F. and
Roberts, S.G. (2012) Repression of transcription by WT1-BASP1 requires the
myristoylation of BASP1 and the PIP2-dependent recruitment of histone deacetylase. Cell
Rep. 2, 462–469 CrossRef PubMed
44 Martelli, A.M., Gilmour, R.S., Neri, L.M., Manzoli, L., Corps, A.N. and Cocco, L. (1991)
Mitogen-stimulated events in nuclei of Swiss 3T3 cells. Evidence for a direct link between
changes of inositol lipids, protein kinase C requirement and the onset of DNA synthesis.
FEBS Lett. 283, 243–246 CrossRef PubMed
45 Ho, K.K., Anderson, A.A., Rosivatz, E., Lam, E.W., Woscholski, R. and Mann, D.J. (2008)
Identification of cyclin A2 as the downstream effector of the nuclear phosphatidylinositol
4,5-bisphosphate 4 network. J. Biol. Chem. 283, 5477–5485 CrossRef PubMed
46 Ahn, J.Y., Liu, X., Cheng, D., Peng, J., Chan, P.K., Wade, P.A. and Ye, K. (2005)
Nucleophosmin/B23, a nuclear PI(3,4,5)P(3) receptor, mediates the antiapoptotic actions
of NGF by inhibiting CAD. Mol. Cell 18, 435–445 CrossRef PubMed
47 Radomski, N. and Jost, E. (1995) Molecular cloning of a murine cDNA encoding a novel
protein, p38-2G4, which varies with the cell cycle. Exp. Cell Res. 220, 434–445
CrossRef PubMed
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence 4.0 (CC BY).
PtdIns(3,4,5)P3–EBP1 association via a polybasic motif in the nucleolus 2047
48 Lamartine, J., Seri, M., Cinti, R., Heitzmann, F., Creaven, M., Radomski, N., Jost, E.,
Lenoir, G.M., Romeo, G. and Sylla, B.S. (1997) Molecular cloning and mapping of a
human cDNA (PA2G4) that encodes a protein highly homologous to the mouse cell cycle
protein. Cytogenet. Cell Genet. 78, 31–35 CrossRef
49 Hamburger, A.W. (2008) The role of ErbB3 and its binding partners in breast cancer
progression and resistance to hormone and tyrosine kinase directed therapies. J.
Mammary Gland. Biol. Neoplasia 13, 225–233 CrossRef PubMed
50 Yoo, J.Y., Wang, X.W., Rishi, A.K., Lessor, T., Xia, X.M., Gustafson, T.A. and Hamburger,
A.W. (2000) Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this
binding by heregulin. Br. J. Cancer 82, 683–690 CrossRef PubMed
51 Liu, Z., Ahn, J.Y., Liu, X. and Ye, K. (2006) Ebp1 isoforms distinctively regulate cell
survival and differentiation. Proc. Natl. Acad. Sci. U.S.A. 103, 10917–10922
CrossRef PubMed
52 Xia, X., Cheng, A., Lessor, T., Zhang, Y. and Hamburger, A.W. (2001) Ebp1, an ErbB-3
binding protein, interacts with Rb and affects Rb transcriptional regulation. J. Cell.
Physiol. 187, 209–217 CrossRef PubMed
53 Squatrito, M., Mancino, M., Donzelli, M., Areces, L.B. and Draetta, G.F. (2004) EBP1 is a
nucleolar growth-regulating protein that is part of pre-ribosomal ribonucleoprotein
complexes. Oncogene 23, 4454–4465 CrossRef PubMed
54 Liu, Z., Oh, S.M., Okada, M., Liu, X., Cheng, D., Peng, J., Brat, D.J., Sun, S.Y., Zhou, W.,
Gu, W. and Ye, K. (2009) Human BRE1 is an E3 ubiquitin ligase for Ebp1 tumor
suppressor. Mol. Biol. Cell 20, 757–768 CrossRef PubMed
55 Mei, Y., Zhang, P., Zuo, H., Clark, D., Xia, R., Li, J., Liu, Z. and Mao, L. (2014) Ebp1
activates podoplanin expression and contributes to oral tumorigenesis. Oncogene 33,
3839–3850 CrossRef PubMed
56 Keller, R. (2004) The Computer Aided Resonance Assignment Tutorial, Cantina, Goldau.
57 Marsh, J.A., Singh, V.K., Jia, Z. and Forman-Kay, J.D. (2006) Sensitivity of secondary
structure propensities to sequence differences between alpha- and gamma-synuclein:
implications for fibrillation. Protein Sci. 15, 2795–2804 CrossRef PubMed
58 Mukai, T., Kusaka, M., Kawabe, K., Goto, K., Nawata, H., Fujieda, K. and Morohashi, K.
(2002) Sexually dimorphic expression of Dax-1 in the adrenal cortex. Genes. Cells 7,
717–729 CrossRef PubMed
59 Reyes, J.C., Muchardt, C. and Yaniv, M. (1997) Components of the human SWI/SNF
complex are enriched in active chromatin and are associated with the nuclear matrix. J.
Cell Biol. 137, 263–274 CrossRef PubMed
60 Lemmon, M.A. (2008) Membrane recognition by phospholipid-binding domains. Nat.
Rev. Mol. Cell Biol. 9, 99–111 CrossRef PubMed
61 Heo, W.D., Inoue, T., Park, W.S., Kim, M.L., Park, B.O., Wandless, T.J. and Meyer, T.
(2006) PI(3,4,5)P3 and PI(4,5)P2 lipids target proteins with polybasic clusters to the
plasma membrane. Science 314, 1458–1461 CrossRef PubMed
62 Martin, T.F. (1998) Phosphoinositide lipids as signaling molecules: common themes for
signal transduction, cytoskeletal regulation, and membrane trafficking. Annu. Rev. Cell
Dev. Biol. 14, 231–264 CrossRef PubMed
63 Gelato, K.A., Tauber, M., Ong, M.S., Winter, S., Hiragami-Hamada, K., Sindlinger, J.,
Lemak, A., Bultsma, Y., Houliston, S., Schwarzer, D. et al. (2014) Accessibility of different
histone H3-binding domains of UHRF1 is allosterically regulated by phosphatidylinositol
5- phosphate. Mol. Cell 54, 905–919 CrossRef PubMed
64 Scott, M.S., Troshin, P.V. and Barton, G.J. (2011) NoD: a nucleolar localization sequence
detector for eukaryotic and viral proteins. BMC Bioinformatics 12, 317 CrossRef PubMed
65 Okada, M., Jang, S.W. and Ye, K. (2007) Ebp1 association with nucleophosmin/B23 is
essential for regulating cell proliferation and suppressing apoptosis. J. Biol. Chem. 282,
36744–36754 CrossRef PubMed
66 Kumar, A., Redondo-Munoz, J., Perez-Garcia, V., Cortes, I., Chagoyen, M. and Carrera,
A.C. (2011) Nuclear but not cytosolic phosphoinositide 3-kinase beta has an essential
function in cell survival. Mol. Cell Biol. 31, 2122–2133 CrossRef PubMed
67 Wishart, D.S. and Sykes, B.D. (1994) Chemical shifts as a tool for structure
determination. Methods Enzymol 239, 363–392 CrossRef PubMed
68 Kjaergaard, M. and Poulsen, F.M. (2012) Disordered proteins studied by chemical shifts.
Prog. Nucl. Magn. Reson. Spectrosc. 60, 42–51 CrossRef PubMed
69 Kowalinski, E., Bange, G., Bradatsch, B., Hurt, E., Wild, K. and Sinning, I. (2007) The
crystal structure of Ebp1 reveals a methionine aminopeptidase fold as binding platform
for multiple interactions. FEBS Lett. 581, 4450–4454 CrossRef PubMed
70 Lessor, T.J., Yoo, J.Y., Xia, X., Woodford, N. and Hamburger, A.W. (2000) Ectopic
expression of the ErbB-3 binding protein ebp1 inhibits growth and induces differentiation
of human breast cancer cell lines. J. Cell. Physiol. 183, 321–329
CrossRef PubMed
71 Zhang, Y., Wang, X.W., Jelovac, D., Nakanishi, T., Yu, M.H., Akinmade, D., Goloubeva, O.,
Ross, D.D., Brodie, A. and Hamburger, A.W. (2005) The ErbB3-binding protein Ebp1
suppresses androgen receptor- mediated gene transcription and tumorigenesis of
prostate cancer cells. Proc. Natl. Acad. Sci. U.S.A. 102, 9890–9895
CrossRef PubMed
72 Yu, Y., Chen, W., Zhang, Y., Hamburger, A.W., Pan, H. and Zhang, Z. (2007) Suppression
of salivary adenoid cystic carcinoma growth and metastasis by ErbB3 binding protein
Ebp1 gene transfer. Int. J. Cancer 120, 1909–1913 CrossRef PubMed
73 Hu, B., Xiong, Y., Ni, R., Wei, L., Jiang, D., Wang, G., Wu, D., Xu, T., Zhao, F., Zhu, M. and
Wan, C. (2014) The downregulation of ErbB3 binding protein 1 (EBP1) is associated with
poor prognosis and enhanced cell proliferation in hepatocellular carcinoma. Mol. Cell
Biochem. 396, 175–185 CrossRef PubMed
74 Liu, H., Li, Z., Li, L., Peng, H. and Zhang, Z. (2015) EBP1 suppresses growth, migration,
and invasion of thyroid cancer cells through upregulating RASAL expression. Tumour.
Biol. 36, 8325–8331 CrossRef PubMed
75 Zhang, Y., Lu, Y., Zhou, H., Lee, M., Liu, Z., Hassel, B.A. and Hamburger, A.W. (2008)
Alterations in cell growth and signaling in ErbB3 binding protein-1 (Ebp1) deficient mice.
BMC Cell Biol. 9, 69 CrossRef PubMed
76 Figeac, N., Serralbo, O., Marcelle, C. and Zammit, P.S. (2014) ErbB3 binding protein-1
(Ebp1) controls proliferation and myogenic differentiation of muscle stem cells. Dev. Biol.
386, 135–151 CrossRef PubMed
77 Monie, T.P., Perrin, A.J., Birtley, J.R., Sweeney, T.R., Karakasiliotis, I., Chaudhry, Y.,
Roberts, L.O., Matthews, S., Goodfellow, I.G. and Curry, S. (2007) Structural insights into
the transcriptional and translational roles of Ebp1. EMBO J. 26, 3936–3944
CrossRef PubMed
78 Squatrito, M., Mancino, M., Sala, L. and Draetta, G.F. (2006) Ebp1 is a dsRNA-binding
protein associated with ribosomes that modulates eIF2alpha phosphorylation. Biochem.
Biophys. Res. Commun. 344, 859–868 CrossRef PubMed
79 Viiri, K.M., Korkeamaki, H., Kukkonen, M.K., Nieminen, L.K., Lindfors, K., Peterson, P.,
Maki, M., Kainulainen, H. and Lohi, O. (2006) SAP30L interacts with members of the
Sin3A corepressor complex and targets Sin3A to the nucleolus. Nucleic Acids Res. 34,
3288–3298 CrossRef PubMed
80 Jian, S., Yixi, L., Zhen, T., Liang, G., Shu Chi, X. and Youcheng, Y. (2012) Expression of
ERBB3 binding protein 1 (EBP1) in salivary adenoid cystic carcinoma and its
clinicopathological relevance. BMC Cancer 12, 499 CrossRef PubMed
81 Kumar, A., Fernandez-Capetillo, O. and Carrera, A.C. (2010) Nuclear phosphoinositide
3-kinase beta controls double-strand break DNA repair. Proc. Natl. Acad. Sci. U.S.A. 107,
7491–7496 CrossRef PubMed
82 Mortier, E., Wuytens, G., Leenaerts, I., Hannes, F., Heung, M.Y., Degeest, G., David, G.
and Zimmermann, P. (2005) Nuclear speckles and nucleoli targeting by PIP2-PDZ domain
interactions. EMBO J. 24, 2556–2565 CrossRef PubMed
83 Sobol, M., Yildirim, S., Philimonenko, V.V., Marasek, P., Castano, E. and Hozak, P. (2013)
UBF complexes with phosphatidylinositol 4,5-bisphosphate in nucleolar organizer
regions regardless of ongoing RNA polymerase I activity. Nucleus 4, 478–486
CrossRef PubMed
84 Yildirim, S., Castano, E., Sobol, M., Philimonenko, V.V., Dzijak, R., Venit, T. and Hozak, P.
(2013) Involvement of phosphatidylinositol 4,5-bisphosphate in RNA polymerase I
transcription. J. Cell Sci. 126, 2730–2739 CrossRef PubMed
85 Marques, M., Kumar, A., Cortes, I., Gonzalez-Garcia, A., Hernandez, C., Moreno-Ortiz,
M.C. and Carrera, A.C. (2008) Phosphoinositide 3-kinases p110alpha and p110beta
regulate cell cycle entry, exhibiting distinct activation kinetics in G1 phase. Mol. Cell Biol.
28, 2803–2814 CrossRef PubMed
86 Chukkapalli, V., Oh, S.J. and Ono, A. (2010) Opposing mechanisms involving RNA and
lipids regulate HIV-1 Gag membrane binding through the highly basic region of the matrix
domain. Proc. Natl. Acad. Sci. U.S.A. 107, 1600–1605 CrossRef PubMed
87 Hisaoka, M., Nagata, K. and Okuwaki, M. (2014) Intrinsically disordered regions of
nucleophosmin/B23 regulate its RNA binding activity through their inter- and
intra-molecular association. Nucleic Acids Res. 42, 1180–1195 CrossRef PubMed
Received 1 April 2016/22 April 2016; accepted 26 April 2016
Accepted Manuscript online 26 April 2016, doi:10.1042/BCJ20160274
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence 4.0 (CC BY).
